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ABSTRACT
Objective: The use of methylphenidate (MPH) in the treatment of attention-deficit/hyperac-
tivity disorder (ADHD) is widely accepted; however, there is increased concern regarding its
abuse potential. Few studies have examined the reinforcing effects of drugs in individuals re-
ceiving them for clinical purposes. This study attempts to assess MPH preference in children
with ADHD using a choice procedure in order to explore the relationship among drug prefer-
ence, clinical efficacy, and abuse potential.
Methods: Participants were 5 children (10–14 years of age) receiving MPH for the treatment of
ADHD. Reinforcing effects were assessed using a double-blind choice procedure, with six sam-
pling sessions and six choice sessions. Participant-rated effects were measured using self-report
questionnaires. Clinical effects were measured using direct observations and behavior ratings.
Results: Differences between the number of MPH, Placebo, and Neither choices across par-
ticipants were significant (2 = 9.6; p < 0.01). Three of five participants reliably chose MPH
more often than placebo. MPH produced idiosyncratic patterns of participant-rated effects
but failed to produce significant clinical effects.
Conclusions: These findings add to the literature on the reinforcing effects of MPH and are
the first reported in a clinical sample of children. Further research exploring the role of clini-
cal efficacy in MPH preference is warranted.
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INTRODUCTION
ATTENTION-DEFICIT/HYPERACTIVITY DISORDER (ADHD)is one of the most commonly diagnosed
childhood psychiatric disorders in the United
States, functionally impairing 3%–5% of the
school-age population (APA 2000). ADHD is
characterized by a persistent pattern of inat-
tention and/or impulsivity-hyperactivity that
is more frequent and severe than typically ob-
served in individuals at comparable levels of
development (APA 2000). To address these be-
havioral problems, most individuals diagnosed
with ADHD receive pharmacological treatment,
with the majority of prescribed products being
methylphenidate-based (Robinson et al. 1999;
Zarin et al. 1998; Zito et al., 2000).
Methylphenidate (MPH) has been shown to
have positive effects across a wide range of do-
mains (DuPaul et al. 1998; Greenhill 1998) in-
cluding: Academic productivity and accuracy
(DuPaul et al. 1994; Elia et al. 1993); fidgetiness
and motor restlessness (DuPaul et al. 1994);
parent and teacher behavior ratings (Barkley
1Department of Pediatrics, University of Michigan Health System, Ann Arbor, MI.
2Department of Psychiatry, Duke University Medical Center, Durham, NC.
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1991); aggression and other antisocial behavior
(Bukstein and Kolko 1998), and social func-
tioning and peer relations (Barkley 1989). Al-
though MPH is associated with a wide range
of clinically beneficial effects, the specific
mechanisms by which the drug alters behavior
have not been conclusively determined. From
a neuropharmacological perspective, MPH is
believed to exert its clinical effects through its
action on noradrenergic and dopaminergic
pathways (Solanto 2000). Specifically, the in-
crease in intrasynaptic dopamine through a
blockade of the dopamine transporter by MPH
is hypothesized to attenuate deficits in in-
hibitory control and working memory that are
hallmarks of ADHD (Greenhill et al. 1999).
More recent work has proposed that MPH also
serves to increase the salience of relevant envi-
ronmental stimuli and that this may be an-
other potential mechanism underlying clinical
effects (Volkow et al. 2004).
Because MPH also exerts dopaminergic ef-
fects in the ventral tegmental area and nucleus
accumbens through the mesolimbic pathway,
it has been hypothesized to influence behavior
by altering behavioral reinforcement processes
(Johansen et al. 2002; Solanto 2000). Some sup-
port has been generated for this explanation of
the behavioral mechanism of MPH. For exam-
ple, one study demonstrated that MPH altered
the rewarding properties of different kinds of
stimuli in children with ADHD (Northup et al.
1997). Other studies have demonstrated that,
compared to nondrug conditions, MPH changes
the manner in which children with ADHD al-
locate their behavior across alternatives that
produce rewards at different rates (Kollins et
al. 1997; Murray and Kollins 2000).
In addition to altering reinforcement pro-
cesses, MPH has been shown to function as a
reinforcer itself through self-administration par-
adigms in nonhuman species (Aigner and Bal-
ster 1979; Johanson and Schuster 1975; Risner
and Jones 1975). Traditionally, the reinforcing
effects of a drug are considered to be one of the
most powerful predictors of abuse because of
the close correspondence between reinforcing
effects and other measures of abuse potential
(Balster and Bigelow 2003; Fischman 1989).
However, only five published studies have di-
rectly examined the reinforcing effects of MPH
in humans, and results have been mixed. Two
studies assessed the reinforcing effects of MPH,
using a choice procedure in healthy adult par-
ticipants. One of these reported that MPH was
chosen on only 27.6% of choices, compared to
placebo (8.6% of choices), and no capsules
(63.8% of choices; Chait 1994); while the other
study reported that 10 mg of MPH was reli-
ably chosen more often than placebo but only
when participants were sleep-deprived (Roehrs
et al. 1999). Two additional studies reported that
MPH administered either orally or intranasally
produced dose-dependent reinforcing effects
in healthy adults using two different assays
(progressive ratio procedure, Rush et al. 2001;
multiple choice procedure, Stoops et al. 2003).
To date, only one study has experimentally
assessed the abuse potential of MPH in indi-
viduals with ADHD who are prescribed the
drug for clinical purposes (Fredericks and
Kollins 2004). In this study, MPH preference
was assessed in a group of young adults diag-
nosed with ADHD using a double-blind choice
procedure. Results indicated that, as a group,
participants chose to take MPH significantly
more frequently than they chose to take either
placebo or no capsule. These results suggest
that MPH produces reinforcing effects in indi-
viduals with ADHD, yet these effects were
more closely associated with clinical efficacy
than with abuse potential of the drug. Specifi-
cally, the participants who chose MPH reliably
exhibited a greater reduction in ADHD symp-
toms following MPH administration and re-
ported more effectiveness of their medication
outside the context of the study. Thus, the rein-
forcing effects of MPH were seemingly associ-
ated with contextual variables of attentional
disturbances such that the more effective MPH
was in reducing ADHD symptoms, the more
likely it was chosen over placebo.
This study is consistent with other research
investigating the reinforcing effects of drugs in
clinical samples to whom they are typically
prescribed. For example, the reinforcing effects
of diazepam and alprazolam—sedatives that
have clearly demonstrated abuse potential in
nonclinical samples (e.g., Gomez et al. 2002;
Juergens 1991; Woods and Winger 1995)—have
been examined in individuals diagnosed with
varying levels of clinically significant anxiety
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(McCracken et al. 1990; Roache et al. 1997; de
Wit et al. 1986). In one study, volunteers with
either generalized anxiety disorder or panic dis-
order preferred alprazolam significantly more
than placebo under free-choice, double-blind
conditions. The patterns of self-administration
and subjective effects, however, were not sug-
gestive of misuse or abuse potential in this
study (Roache et al. 1997). The implication of
this study is that in clinical samples, the rein-
forcing effects of a drug may be more associ-
ated with therapeutic efficacy than with the
potential for abuse and that the examination of
both subjective effects and reinforcing effects
is necessary to make this important distinction.
In the past decade, the therapeutic use of
MPH has increased, leading to debates sur-
rounding the prescription rates and safety of
this stimulant drug (Rappley 1997). Critics
argue that MPH is overprescribed (see Safer et
al. 2000 for a discussion) and that early stimu-
lant treatment predisposes individuals with
ADHD to develop problems with substance
abuse (e.g., Lambert and Hartsough 1998). Al-
though mounting evidence suggests the oppo-
site to be true (i.e., that stimulant treatment for
ADHD serves a protective function for the de-
velopment of substance use disorders; Wilens
et al. 2003), the reinforcing effects of MPH have
only begun to be studied in patients for whom
the medication is known to have clinical bene-
fits (Fredericks and Kollins 2004). The reinforc-
ing effects of MPH have not been assessed in
children diagnosed with ADHD. Thus, the
purpose of this study was to conduct a pilot
investigation of MPH preference and partici-
pant-rated effects in children diagnosed with
ADHD to further explore the distinction be-




Participants for this study were 4 males (10–
14 years of age) and 1 female (10 years of age),
recruited through local physicians and psy-
chologists, recruitment flyers, and word of
mouth on the basis of two criteria: (1) an estab-
lished diagnosis of ADHD; and (2) a current
prescription for MPH for the treatment of symp-
toms associated with ADHD. At the time of the
study, all participants were receiving immedi-
ate-release MPH and had been receiving MPH
treatment for at least 1 year prior to selection
for the study. Parents provided informed con-
sent, and participants provided verbal assent
to participate.
To corroborate the ADHD diagnostic status
of participants and to ensure a homogeneous
group, the participants’ parents, or one parent
and another individual with whom the child
had significant contact, completed the Child
Behavior Checklist (CBCL; Achenbach and
Edelbrock 1993; inclusion criterion = Atten-
tional Problems subscales T score  65); and
the Conners’ Parent Rating Scale-48 (CPRS-48;
Conners 1990; inclusion criterion = Impulsive-
Hyperactive Scale T score  65). These instru-
ments are used commonly in the assessment of
ADHD, have adequate psychometric proper-
ties, and good predictive validity for identify-
ing children with ADHD (e.g., Conners 1990;
Hudziak et al. 2004). Parents were instructed
to complete the rating forms based on their
child’s behavior when he or she was not on his
or her medication. In addition, all participants
had been previously diagnosed by pediatri-
cians, family physicians, and/or other quali-
fied clinicians and had been receiving MPH for
at least 1 year. The primary care physicians for
each participant also reviewed the protocol,
approved participation and provided prescrip-
tions for placebo pills and for the participant’s
normal dose of MPH. At the time of the study,
all subjects were receiving immediate-release
formulation MPH. Table 1 provides background
information for each of the participants.
Participants were excluded from the study if
they were taking any other type of psychoac-
tive medication, exhibited any gross neurolog-
ical, sensory, or motor impairment, had a
history of other significant learning or psychi-
atric problems, and/or had a known family
history of diabetes.* A total of 14 children were
METHYLPHENIDATE PREFERENCE IN CHILDREN 731
*This exclusionary criterion was added at the request of
the local IRB, as the placebo pills contained sugar. No
participants were excluded for this reason.
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screened and 9 were excluded for the follow-
ing reasons: receiving psychoactive medications
in addition to MPH (4 children), not currently
receiving MPH treatment (2 children), could
not commit to the length of the study (2 chil-
dren), did not meet age requirements (1 child).
Participants received monetary compensa-
tion for their participation in the 13 sessions. In
addition, during experimental sessions, partici-
pants received assistance with outside home-
work assignments and practiced basic academic
skills. The Human Subjects Institutional Review
Board at Western Michigan University, Kalama-
zoo, MI, approved this work.
Procedure
Volunteers participated in 13 sessions. The
first session was a screening session wherein
the participant’s parent completed the CBCL
(Achenbach and Edelbrock 1993) and the
CPRS-48 (Conners 1990). Parents were given
an additional copy of these forms to be com-
pleted by another adult with whom the child
had significant contact. Children were also ad-
ministered a short form of the Wechsler Intelli-
gence Scale for Children, 3rd edition (WISC-III,
Block Design and Vocabulary subtests; Wech-
sler 1991) to screen for intellectual functioning.
The scores obtained on the subtests of the
WISC-III were not used as inclusion criteria.
Rather, they were used to provide an estimate
of the participant’s ability to comprehend the
questionnaires to be used in subsequent ses-
sions. In addition, medical history, comorbid
mental health diagnoses, length of time on
MPH, and dosing information were obtained.
If inclusion criteria were met, the child’s physi-
cian was contacted to provide a prescription
for MPH and placebo capsules.
All drugs were prepared in a standardized
manner by a pharmacist at the University
Health Center who had experience preparing
medications for other research and clinical ac-
tivities in our laboratory. Each participant’s
maintenance dose of methylphenidate and an
inert placebo were each prepared in opaque
capsules (size 01). The participant’s mainte-
nance dose was encapsulated in one capsule,
such that each participant received only one
capsule at a time. Placebo and MPH capsules
were placed in separate bottles labeled as
“Bottle A” and “Bottle B.” The capsule letter
assignments were varied across participants.
Participants were instructed that they would
receive either their typical dose of MPH or
placebo throughout the experiment but were
informed that the same lettered capsule always
contained the same substance.
Experimental sessions
For experimental sessions, participants were
asked to refrain from taking their MPH pre-
scription for at least 4 hours prior to coming
into the laboratory. All participants were tak-
ing their maintenance dose of MPH at noon on
experimental days. According to self-report,
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TABLE 1. SUBJECT DEMOGRAPHICS
Subject Age Height Weight Time on MPH Dose CBCLa CPRS-48b WISC-IIIc
1 10 4'11'' 85 lbs 36 months 10 mg T = 69 T = 72 IQ = 91
(t.i.d)
2 14 5'7'' 200 lbs 60 months 20 mg T = 81 T = 72 IQ = 68
(b.i.d)
3 10 NA NA 36 months 10 mg T = 70 T = 76 IQ = 83
(t.i.d)
4 14 5'2'' 100 lbs 84 months 30 mg T = 78 T = 76 IQ = 126
(t.i.d)
5d 10 5'2'' 100 lbs 12 months 10 mg T = 72 T = 87 IQ = 106
(b.i.d)
aCBCL score represents the Attention Problems subtest score.
bCPRS-48 score represents the Impulsive-Hyperactive subtest score.
cWISC-III IQ score based on Block Design and Vocabulary scores.
dSubjects 1–4 were male and subject 5 was female.
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participants were compliant with taking their
noon dose 95% of the time. Participants 1, 2,
and 4 each missed one of their noon doses,
while participants 3 and 5 received their noon
dose 100% of the time on experimental days.
The 4-hour restriction on their medication ad-
ministration did not deviate significantly from
their typical medication regimen.
Sampling sessions. There were six sampling
sessions, which occurred on Mondays and Tues-
days for 3 weeks. The sampling sessions were
designed to provide participants experience
with the effects of the two drug conditions
(MPH and placebo) on the basis of which they
would subsequently make their drug choice.
During experimental sessions, participants ar-
rived at the laboratory to complete participant-
rated drug effect questionnaires (see Table 2
for timeline). Following the completion of the
questionnaires, the participant took part in the
appropriate drug administration procedures.
During the first sampling session of the week
(on Monday), participants received either
placebo or MPH in a capsule labeled “Pill A”
or “Pill B.” In the second sampling session (on
Tuesday), participants received the other sub-
stance in a capsule labeled with the other let-
ter. Participants also received a wristband
labeled with the same letter as the pill admin-
istered as a reminder of which capsule they re-
ceived that day. Participants were instructed to
associate the effects of the capsule with its let-
ter label. Capsule letter assignments varied
across participants. Participants were informed
that the same letter capsule would always con-
tain the same thing (e.g., “real” medication or
“pretend” medication). The order in which
placebo and MPH were scheduled in the sam-
pling sessions was counterbalanced across sub-
jects and within-subjects across weeks. Drug
administration was double-blind.
After drug-administration procedures, the
participant was walked to an adjacent academic
skills enrichment program. This setting in-
cluded approximately 10 students (K-12), each
of whom received individual instruction in
basic skill areas, such as reading, math, writing,
and spelling. Participants in this study were
not formally enrolled in the tutorial program
but still received individual instruction. They
were seated at individual cubicles and had ac-
cess to a desk and a computer wherein they
worked on various academic tasks. While in
this analog classroom setting, an independent
observer began direct behavioral observations
45 minutes after the drug administration pro-
cedures and observed each subject for three
15-minute intervals using 30-second partial in-
terval recording. During this time, the partici-
pant was directed to work on various math
sheets and was observed for 15 minutes. Data
were collected using the ADHD Behavior Cod-
ing System (Barkley 1990). Following the 15
minutes of independent seat work, the research
participants and other students enrolled in the
tutorial program took a break from academic
work and were encouraged to participate in
the break-time activities. During the break, the
observer recorded behaviors using a Social Sit-
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TABLE 2. AN EXAMPLE OF A SESSION TIMELINE INDICATING THE ORDER OF SESSION EVENTS
Time Activity
1545 hour Arrive at the laboratory and complete participant-rated effects questionnaires.
1600 hour Drug administration procedures
1615 hour Participants are escorted to the Project Help Facility
1645–1700 hour Participants are given math sheets to complete during behavioral observations.
1700–1715 hour Break time. Participants are observed during social interactions.
1720 hour Participants return to the Project Help Facility and are given a second set of math sheets to
1735 hour complete during behavioral observations.
1730 hour Research assistant completes the CTRS-28 form.
1745 hour Participant returns to the lab to complete the participant-rated effects questionnaires.
1815 hour Participant receives monetary compensation.
CTRS-28, Conners Teacher Rating Scale, 28-item version.
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uations Behavioral Coding Form (adapted from
Pelham et al. 1991). Following the break, par-
ticipants returned to the classroom and were
assigned a second set of math sheets and were
observed for 15 minutes using the ADHD Be-
havior Coding System.
Two hours after the ingestion of the capsule
the participant met with the researcher in the
laboratory to complete the participant-rated
effects questionnaires. After the completion of
the questionnaires, the participant received
monetary compensation from the researcher
and was provided with verbal praise for their
cooperation.
Choice sessions. There were six choice sessions,
which occurred on Wednesdays and Thurs-
days for the same 3 weeks as the sampling ses-
sions. In the choice sessions, participants were
presented with three cups: One with “Pill A,”
one with “Pill B,” and an empty cup labeled
“C.” The participant chose one of three op-
tions: To ingest “Pill A,” to ingest “Pill B,” or to
take neither capsule. The use of a “Neither”
option was included to replicate prior exami-
nations of the reinforcing effects of MPH (Chait
1994) and to provide a more reliable measure
of the reinforcing efficacy of the chosen sub-
stance (Spiga and Roache, 1997). The number
of times one substance was chosen over the
other served as an indicator of its relative rein-
forcing effects (de Wit and Griffiths 1991). This
choice procedure is a technique that has been
used to measure the reinforcing effects of a
number of different drugs, in a range of con-
texts and with various subject populations (de
Wit and Griffiths 1991; Foltin and Fischman
1991; Johanson and de Wit 1989). Following
the choice, the child was presented with the
appropriate letter-matched wristband, with
“Neither” being labeled “C.” The procedures
for collecting participant-rated effects, and the
behavioral observations in the academic skills
enrichment program, were identical to those
used in the sampling sessions.
Dependent measures
Drug preference. Drug choice was the primary
measure of drug preference. The number of
times one option (MPH, Placebo, Neither) was
chosen over the other served as an indicator of
its relative reinforcing effects.
Participant-rated effects questionnaires. The
participant-rated effects were assessed at pre-
drug administration, and 1.5 hours postdrug
administration. The participant-rated effects
measures were as follows:
How I Feel Questionnaire. This is a 28-item
questionnaire adapted from the van Kammen-
Murphy Mood Scale (van Kammen and Mur-
phy 1975). Items are rated on a 4-point scale
(0 = Not at all; 1 = A little; 2 = Some; 3 = A lot).
This adapted scale has been used with chil-
dren to measure the subjective effects produced
by caffeine (Elkins et al. 1981) and d-ampheta-
mine (Rapoport et al. 1980).
Profile of Mood States (POMS). A short form of
the POMS was used to assess mood and affective
state. This version consists of 37 items that are
rated on a 5-point scale (0 = Not at all; 1 = A little;
2 = Moderately; 3 = Quite a bit; 4 = Extremely).
Compared to the original 65-item scale (McNair
et al., 1971), the shortened version has been
shown to have adequate psychometric proper-
ties (Shacham 1983). This scale has been used to
assess the effects of stimulants in children
(Walker et al. 1988). Six scales are derived from
the 37 items: Anger/Hostility; Confusion/Be-
wilderment; Depression/Dejection; Fatigue/In-
ertia; Tension/Anxiety, and Vigor/Activity.
Subjective effects rating scale (SERS). This is a
22-item scale developed by Kollins et al. (1998)
to assess the participant-rated effects of methyl-
phenidate and other stimulant medication in
children and adolescents. Items from the ques-
tionnaire are rated on a 4-point scale (0 = Not
at all; 1 = A little; 2 = Some; 3 = A lot). Items on
the SERS were derived from three sources.
Firstly, stimulant-appropriate items from the
Addiction Research Center Inventory (ARCI;
Martin et al. 1971) were selected and changed
to an age-appropriate reading level. Secondly,
items were selected from the Side Effects Rat-
ing Scale (Barkley 1991). Lastly, items were se-
lected based on discussions with clinicians
experienced in working with children diag-
nosed with ADHD.
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Visual Analog Scale (VAS). The VAS consisted
of ten 100-mm horizontal lines, each labeled
with a different item. Each scale was presented
individually. Participants were instructed to
rate each item on the basis of how they felt at
the present time. Each VAS scale was anchored
with “not at all” at the leftmost extreme, and
“very much” at the rightmost extreme. Partici-
pants were instructed to place a mark on each
line indicating how they felt at the moment.
The items rated included Like Drug, Energetic,
Sleepy, Friendly, Restless, Nervous, Hungry,
Excited, Happy, and Feel Like Talking.
Clinical effects
ADHD behavior coding system. While partici-
pants completed their assigned math sheets,
observers recorded the occurrences of off-task
behavior, fidgetiness, vocalizing, playing with
objects, and out of seat behavior using this
coding system (Barkley 1990).
Social Situations Behavioral Coding Form. Ob-
servers recorded the occurrences of positive peer
interactions, conduct problems, noncompliance,
interrupting, and negative verbalizations using
an adapted Social Situations Behavioral coding
form (Pelham et al. 1991).
In order to collect reliability measurements
on the ADHD and social behaviors, a second
independent observer collected data during a
minimum of 25% of the direct observations
across participants. Interobserver agreement
for all 10 categories was calculated separately
by dividing the number of agreements by the
number of agreements and disagreements and
multiplying by 100. Interobserver reliability
was at least 90% for each category for each of
the 5 subjects.
Data analysis
Drug preference. The number of times MPH,
Placebo, and Neither were chosen was taken
as an indicator of participant drug preference
and can be conceptualized as an index of the
drug’s positive reinforcing properties (deWit
et al. 1984). The reinforcing effects of MPH were
assessed by calculating the total number of
choices of MPH, placebo, and neither across
the participants and examining the proportion
of choices with a chi-square analysis.
Clinical effects. Behavioral observations and
the number of math problems attempted and
correctly completed were computed for MPH
and placebo conditions and were analyzed
using paired t tests.
Participant-rated effects. The participant-rated
effects were analyzed for each participant. The
change from baseline ((postdrug administra-
tion scores)  (predrug administration scores))
was computed for each questionnaire item or
factor (e.g., POMS) using raw scores. Compos-
ite scores for each questionnaire were aver-
aged for each participant at both time periods
(pre, 1.5 hour). Separate averages were calcu-
lated for MPH and Placebo Sampling sessions,
as well as for each of the three choices (MPH,
Placebo, Neither) for Choice sessions.
Change scores for each item or factor were
computed for MPH sessions, Placebo sessions,
and Neither sessions. The change scores for each
condition (i.e., MPH, Placebo, Neither) were
averaged for each participant. The average
change scores for each item were then trans-
formed into z-scores. The differences between
z-scores obtained on MPH sampling days and
Placebo sampling days were computed. In ad-
dition, differences between z-scores obtained
on MPH, Placebo, and Neither choice days were
computed. Lastly, differences between z-scores
obtained on overall MPH and No Drug days
(i.e., Placebo or Neither) were compared. Items
that differed from the average by one standard




The results of the choice sessions were ana-
lyzed by examining the percentage of MPH
choices per subject (see Fig. 1). Of 30 total
choices across all participants (six choices each),
MPH was chosen 18 times (60%). Placebo and
neither were each chosen six times (20%). A
chi-square analysis found that the number of
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choices of MPH, Placebo, and Neither differed
significantly (2 = 9.6; p = 0.01).
According to the criteria used by Chait
(1994), participants 2, 4, and 5 were classified
as “MPH choosers” (Fig. 2). Participant 2
chose MPH 4 of 6 times (67%) and placebo
2 of 6 times (33%). Participants 4 and 5 each
chose MPH 5 of 6 times (83%) and Neither
1 time (16%). Participants 1 and 3 did not dem-
onstrate reliable choice patterns and were
classified as “nonchoosers,” even though par-
ticipant 1 chose MPH 3 of 6 times (50%) versus
Placebo 2 of 6 times (33%) and Neither 1 of
6 times (16%). Participant 3 chose MPH 1 of
6 times (16%), Placebo 2 of 6 times (33%), and
Neither 3 of 6 times (50%).
Clinical effects
Initial t tests on the categories used for behav-
ioral observations and academic performance
yielded no significant results. In addition, t
tests on the measures of clinical effects revealed
no significant differences between the sampling
days and choice days. Thus, examining the in-
teractions between the clinical effects, reinforc-
ing effects, and subjective effects of MPH was
not possible.
Participant-rated effects
Table 3 shows the results from the individual-
subject analyses. The patterns of responding
on the participant-rated effects questionnaires
were idiosyncratic. For example, items typi-
cally associated with stimulant properties of
MPH, such as “Feel like Talking,” “Energetic,”
and “Heart Beating Fast,” did not yield consis-
tent response patterns. Specifically, following
MPH administration, some children reported
an increase in these effects, others reported a
decrease, and others reported no change. Like-
wise, responding on items typically associated
with the clinical effects of MPH in ADHD pop-
ulations was also variable. With 1 participant
reporting an increase in “Can Concentrate,”
while 1 reported a decrease and the remaining
3 had no change. It is possible that with a
larger sample, the participant-rated effects may
have been more consistent.
DISCUSSION
The results of this pilot investigation dem-
onstrated significant differences between the
number of MPH, Placebo, and Neither choices
in a sample of children diagnosed with ADHD.
MPH was chosen more frequently than placebo
or no capsules by 4 of 5 participants. In addi-
tion, MPH produced idiosyncratic patterns of
subjective effects but failed to produce signifi-
cant effects on behavior ratings or observations.
These preliminary findings are concordant with
research on the reinforcing effects of MPH in
both nonhuman (Aigner and Balster 1979; Jo-
hanson and Schuster 1975; Risner and Jones
1975) and healthy adult human subjects (Roehrs
et al. 1999; Rush et al. 2000). These findings are
also consistent with another recently published
study with college students with ADHD (Fred-
ericks and Kollins 2004).


























FIG. 1. The percentage of MPH, Placebo, and Neither























FIG. 2. The percentage of MPH, Placebo, and Neither
choices for each participant. MPH = methylphenidate.
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This pilot study has several important im-
plications. Firstly, it adds to a sparse literature
on the reinforcing effects of MPH in humans
and is the first to study these effects in a sam-
ple of children receiving the drug for clinical
purposes. To date, the literature is inconclu-
sive with respect to whether methylphenidate
exerts reinforcing effects in humans. One study
failed to report consistent reinforcing effects
(Chait 1994); one study reported reinforcing
effects under specific conditions of sleep de-
privation (Roehrs et al. 1999); and one study
reported significant reinforcing effects compared
to placebo using a progressive-ratio procedure
(Rush et al. 2000). Our investigation is similar
to the study that examined the reinforcing ef-
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TABLE 3. PARTICIPANT-RATED EFFECTS FOR INDIVIDUAL SUBJECTS
POMS subscales Subject 1 Subject 2 Subject 3 Subject 4 Subject 5
Tension ↓ — ↑ — ↓
Confusion — ↑ — — —
Vigor — — — ↓ —
How I Feel Items Subject 1 Subject 2 Subject 3 Subject 4 Subject 5
Trouble keeping mind on things ↓ — ↓ — —
Restless ↓ — — ↓ —
“Funny” ↑ — — — —
A lot of energy ↓ — — — —
Tired and slow ↑ — — — ↓
Weird, “freaky” — — — — —
No one wants to help me — ↑ — — ↓
Unusual thoughts ↑ — — —
Unhappy — — ↓ — —
Doing a pretty good job — — ↑ — ↑
Something good will happen — — — ↑ ↑
Mad — — — — ↓
Friendly — — — — ↑
Happy — — — — ↑
SERS Subject 1 Subject 2 Subject 3 Subject 4 Subject 5
Feel like talking ↓ — — — ↑
Can concentrate ↑ ↓ — — —
Like joking ↓ ↓ — ↑ —
Hungry ↓ — — — —
Focused on work — ↑ — — —
Popular — ↓ ↓ — —
Get along with others — ↓ — — —
Daydreamed — — ↓ — —
Heart beating fast — — ↓ — ↑
Worked well — — — ↑ —
Excited — — — ↑ —
Visual Analog Scales Subject 1 Subject 2 Subject 3 Subject 4 Subject 5
Energetic ↓ ↓ — — —
Excited — ↓ — — —
Like Drug — — ↑ ↑ —
Sleepy — — — — ↓
Restless — — — — ↓
Note: Arrows indicate a significant deviation from the average change score across sessions. The direction of the
arrows indicates the effect of MPH relative to the “no drug” condition (i.e., placebo or neither). Dashes indicate no
significant differences.
POMS = Profile of Mood States; SERS = Subjective Effects Rating Scale.
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fects under conditions of sleep deprivation
(Roehrs et al. 1999), in that the reinforcing ef-
fects of MPH may have been expressed only
under a particular set of environmental condi-
tions. For example, anecdotal subject comments
suggested that children chose MPH when they
“needed to calm down” or wanted “to be able
to concentrate.” This is also similar to the work
completed by Silverman et al. (1994a, 1994b),
which demonstrated that the behavioral re-
quirements following drug administration (i.e.,
vigilance or relaxation activities) could alter the
self-administration of stimulants (i.e., caffeine
and d-amphetamine) and sedatives (i.e., triazo-
lam). Based on these findings, the authors sug-
gested that drug self-administration is related
to the changes in environmental conditions.
Furthermore, this initial pilot study lends
support to the idea that the reinforcing effects
of a drug, as measured using choice procedures,
are not necessarily associated with abuse po-
tential, especially when assessed in clinical sam-
ples. The reinforcing effects of clinically used
agents may necessitate a different conceptual-
ization of such drug-taking behavior. In these
situations, the choice of drug over placebo may
be reinforced by the consequences of eliminat-
ing aversive stimuli (e.g., anxiety; Roache et al.
1997) or by more positive consequences, such
as being able to work more efficiently, receiv-
ing greater praise from teachers and peers, or
getting better grades (as may be the case with
ADHD). This is also consistent with our previ-
ous study conducted with college students with
ADHD (Fredericks and Kollins 2004). Future
work that examines MPH in a context where
there are measurable clinical changes will be
important to help clarify the functional role of
the reinforcing effects of the drug in this and
other samples.
Despite the implications of this study, sev-
eral important limitations should be addressed.
Firstly, relevant clinical effects were not ob-
served under MPH compared to placebo con-
ditions. Although ADHD behaviors in analog
classrooms and restricted academic situations
are typically sensitive to the effects of stimu-
lant medications (DuPaul et al. 1994; Swanson
et al. 1998a; Swanson et al. 1998b), the setting
used in our study may have precluded the ob-
servation of such clinical effects. In the Project
Help facility, participants in this study received
one-on-one instruction in a cubicle with mate-
rials (computer games) and personnel (under-
graduate tutors) that may have been more
engaging for the participants than those mate-
rials and personnel typically used in a regular
classroom or even an analog classroom setting.
It would have been useful to collect concurrent
data to corroborate the clinical effectiveness of
the participant’s medication in their regular
classroom setting. Thus, it will be beneficial to
replicate this study in a normal classroom set-
ting (Abikoff and Gittelman 1985; Rapport et
al. 1994), so as to gain a fuller understanding
of the interaction between reinforcing and clin-
ical drug effects in children with ADHD. It is
also possible that the reinforcing effects of MPH
that were observed reflected changes in moti-
vation or alterations in the saliency of relevant
environmental stimuli (e.g., Volkow et al. 2004)
that our clinical battery was not able to assess.
Future work would be well served to deter-
mine whether reliable MPH choice on clinical
sample is associated with such endpoints.
A second limitation of our study surrounds
the collection of participant-rated effects. Al-
though the questionnaires used in this study
have been used to measure subjective effects in
children, the psychometric integrity of these
instruments has not been determined in these
populations. In addition, the reading level of
the children may have affected the manner in
which the subjective effects were evaluated,
such that the participants may not have fully
understood the items on the questionnaires.
Thus, the lack of reading comprehension may
have contributed to within-subject variability
on the measures of subjective effects. The vari-
able subjective effects reported by participants
in this study may also reflect the possibility
that stimulant drugs, such as MPH, produce
different subjective effects among individuals
diagnosed with ADHD as compared to nondi-
agnosed individuals. Indeed, among college
students diagnosed with ADHD, MPH was
associated with variable stimulant-rated sub-
jective effects (Fredericks and Kollins 2004).
Specifically, MPH decreased ADHD symp-
toms without significant changes in ratings of
stimulant-like effects (e.g., “high”). This possi-
bility is supported by studies reporting differ-
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ential levels of dopamine transporter in the
brains of ADHD individuals compared with
non-ADHD controls, providing a possible neu-
ropharmacological mechanism for the differen-
tial subjective effects (Krause et al. 2003).
Perhaps the biggest limitation of this study
was our small sample size, which clearly limits
the generalizability of the results. Previous stud-
ies examining the reinforcing effects of MPH in
adults used larger sample sizes (n = 35, Chait
1994; n = 6, Roehrs et al. 1999; n = 8, Rush et al.
2000). Thus, in order to draw more confident
conclusions about the reinforcing effects of MPH
in children with ADHD, it will be important to
replicate these findings with a larger subject
population, while keeping in mind the practi-
cal and ethical challenges involved in doing this
kind of work with clinical groups. One strat-
egy for doing so might be to use less stringent
entry criteria. Seven children were excluded
from participating in the study because they
were concomitantly receiving other medica-
tions, were not currently prescribed MPH, or
did not meet minimum age criteria. Although
the inclusion of heterogeneous participants with
respect to these criteria would surely introduce
additional variance to the obtained results,
doing so might also help identify important in-
dividual differences in the reinforcing effects
of MPH in a clinical sample.
CONCLUSIONS
In summary, the results of this pilot investi-
gation suggest that MPH functions as a rein-
forcer in children for whom it is prescribed for
the treatment of ADHD. These findings add to
a growing literature on the reinforcing effects
of this stimulant in humans and are the first to
report such findings in a clinical sample of chil-
dren. Because we did not observe reliable clin-
ical effects of the drug, it is difficult to fully
ascertain the implications of these findings in
the context of clinical psychopharmacology. In
any case, extension of the work begun here
will be important to help understand the be-
havioral mechanism of action of MPH. Secon-
darily, further study of the reinforcing effects
of MPH in individuals with ADHD may also
shed light on the self-evaluations and attribu-
tional style of children diagnosed with ADHD
and the abuse potential of MPH in individuals
with ADHD.
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